Reuters logo
2 个月内
BRIEF-Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology
2017年6月12日 / 晚上8点15分 / 2 个月内

BRIEF-Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology

1 分钟阅读

June 12 (Reuters) - Adamas Pharmaceuticals Inc

* Adamas announces publication of ADS-5102 phase 3 EASE LID clinical trial in JAMA Neurology

* Adamas Pharmaceuticals Inc - new drug application for ADS-5102 currently under FDA review with August 24, 2017 PDUFA date Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below